Dr. Agarwal's Health Care Limited (NSE:AGARWALEYE)
India · Delayed Price · Currency is INR 468.00
+2.20 (0.47%)
Oct 19, 2026, 3:29 PM IST
Dr. Agarwal's Health Care Revenue
Dr. Agarwal's Health Care had revenue of 6.14B INR in the quarter ending June 30, 2026, with 25.97% growth. This brings the company's total for the last twelve months to 22.07B, up 22.94% year-over-year. In the fiscal year ending March 31, 2026, Dr. Agarwal's Health Care had annual revenue of 20.80B with 21.57% growth. That makes Dr. Agarwal's Health Care the 16,343rd largest company in the world by revenue and 852nd in India.
Revenue (ttm)
22.07B
Revenue Growth
+22.94%
P/S Ratio
6.73
Revenue / Employee
n/a
Employees
n/a
Market Cap
148.46B
Revenue by Geography
- India 18.71B 89.9%
- outside India 2.09B 10.1%
Fiscal year ended Mar 31, 2026 See the full Dr. Agarwal's Health Care breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 20.80B | 3.69B | 21.57% |
| Mar 31, 2025 | 17.11B | 3.79B | 28.44% |
| Mar 31, 2024 | 13.32B | 3.14B | 30.86% |
| Mar 31, 2023 | 10.18B | 3.22B | 46.25% |
| Mar 31, 2022 | 6.96B | 2.25B | 47.73% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 599.11B |
| Divi's Laboratories | 112.30B |
| Lenskart Solutions | 96.34B |
| Alembic Pharmaceuticals | 77.84B |
| Laurus Labs | 72.70B |
| Indegene | 38.13B |
| NATCO Pharma | 34.85B |
| Eris Lifesciences | 32.12B |